Presentations

      Inflammatory Processes In A Mouse Model Of Chronic Pulmonary Diseases By Cigarette Smoke Inhalation

      H-Haussmann, H-J. Haussmann.; Van Miert, E.; Stinn, W.
      Conference date
      Sep 14, 2009
      Conference name
      Eurotox 2009
      Link to more information
      Link to more information
      Topic
      Summary

      Laboratory animal models can help to improve our understanding of the mechanistic basis of chronic smoking-related diseases such as emphysema and lung cancer. A/J mice were whole-body exposed to fresh air or to cigarette mainstream smoke from a research reference cigarette in various combinations of inhalation and post-inhalation periods of up to 18 months at daily doses of total particulate matter of up to 3000 mg/m(3) x h. Genes involved in xenobiotic metabolism (e.g., CYP1A1) and oxidative stress (HMOX1) were found to be transiently induced during inhalation periods, returning to control levels directly after cessation of smoke exposure. Genes involved in inflammatory processes (MIP-1alpha) or proteolytic processes (MMP12) displayed sustained induction. Similarly, inflammatory cells and several protein markers in bronchoalveolar lavage showed either a transient induction pattern (PMNLS, TNF-alpha) or a sustained induction pattern (lymphocytes, KC). After 5 months of inhalation, altered lung mechanics (higher tissue elastance and partial loss of elastic recoil) and emphysematous changes (increased mean chord length, decreased bronchial attachments) were observed. In studies of up to 18 months, a dose-dependent increase in the multiplicity of adenomas and adenocarcinomas in the lungs was observed. The causal role of the inflammatory effects in the chronic pathogeneses developing in this mouse model and their relevance to human smoking-related diseases remain to be established. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.